FDA approves expanded use of Bristol Myers' cancer cell therapy

The U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's (BMY.N) cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular lymphoma, that has returned or has not responded to prior treatments.